Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by GRAY, C. S.
Right arrow Articles by BATES, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GRAY, C. S.
Right arrow Articles by BATES, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 Oxford University Press

research-article

A Randomized Double-blind Controlled Trial of Naftidrofuryl in Acute Stroke

CHRISTOPHER S. GRAY*, JOYCE M. FRENCH, GRAHAM S. VENABLES, NIALL E. F. CARTLIDGE, OLIVER F. W. JAMES and DAVID BATES

Departments of Neurology and Geriatrics, Royal Victoria Infirmary Newcastle upon Tyne
Royal Hallamshire Hospital Sheffield
Department of Geriatrics, University of Newcastle upon Tyne

*Address correspondence to Dr C. S Gray, Department of Geriatrics, City Hospital, Greenbank Drive, Edmburgh EH10 5SB

There is evidence to support the use of naftidrofuryl in acute stroke with claims of increased recovery, reduced fatality and reduced bed occupancy in patients treated with either oral or intravenous preparations. One hundred patients presenting with acute hemisphere stroke (< 72 hours) were randomized to receive either a new oral formulation of naftidrofuryl or placebo on a double-blind basis. Treatment was given for a total of 12 weeks and patients followed for 26 weeks with serial neurological and functional assessments by a single observer. Cumulative fatality and hospital-bed occupancy were determined at each assessment interval. No significant difference was demonstrated in cumulative fatality, hospital-bed occupancy or recovery of motor function in patients treated with either naftidrofuryl or placebo. There is no evidence from this study to support the use of oral naftidrofuryl in acute stroke.

Revision received March 6, 1990.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 StrokeHome page
K. Uchino, D. Billheimer, and S. C. Cramer
Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials
Stroke, April 1, 2001; 32(4): 909 - 916.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
P. W. Duncan, H. S. Jorgensen, and D. T. Wade
Outcome Measures in Acute Stroke Trials : A Systematic Review and Some Recommendations to Improve Practice
Stroke, June 1, 2000; 31(6): 1429 - 1438.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
M. Davis and D. Barer
Neuroprotection in acute ischaemic stroke. II: Clinical potential
Vascular Medicine, August 1, 1999; 4(3): 149 - 163.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.